𝔖 Bobbio Scriptorium
✦   LIBER   ✦

5016 Efficacy in patient subgroups in RIBBON-1, a randomized, double-blind, Phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC)

✍ Scribed by V. Dieras; J. Glaspy; A. Brufsky; I. Bondarenko; O. Lipatov; E.A. Perez; S. Chan; X. Zhou; S.C. Phan; N. Robert

Book ID
119600666
Publisher
Elsevier Science
Year
2009
Tongue
English
Weight
49 KB
Volume
7
Category
Article
ISSN
1359-6349

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

8LBA Biomarker evaluation in the randomi
8LBA Biomarker evaluation in the randomized, double-blind, placebo-controlled, Phase IIIb ATLAS Trial, comparing bevacizumab (B) therapy with or without erlotinib (E), after completion of chemotherapy with B for the treatment of locally-advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC)
✍ B. Johnson; V. Miller; L. Amler; H. Stern; C. Soh; P. O'Connor; F. Kabbinavar πŸ“‚ Article πŸ“… 2009 πŸ› Elsevier Science 🌐 English βš– 68 KB
A Phase 2b, Double-Blind, Randomized Stu
A Phase 2b, Double-Blind, Randomized Study Evaluating the Efficacy and Safety of Sorafenib (SOR) Compared With Placebo (PBO) When Administered in Combination With Chemotherapy (Modified FOLFOX6) for First-line Treatment (tx) of Patients (Pts) With Metastatic Colorectal Cancer (mCRC). The RESPECT Trial
✍ J. Tabernero; R. Garcia-Carbonero; C.H. KΓΆnne; P.J. O'Dwyer; A. Sobrero; E. Van πŸ“‚ Article πŸ“… 2011 πŸ› Elsevier Science 🌐 English βš– 50 KB